Pharmacy Drug Policy & Procedure
Policy Name: Evenity (romosozumab) Policy #: 2756P
Purpose of the Policy
The purpose of this policy is to define the criteria for coverage of Evenity.
Statement of the Policy
Health Alliance Medical Plans will approve the use of Evenity under the medical specialty benefit when the
following criteria have been met.
Criteria
1. Coverage Criteria
1.1 Documented diagnosis of osteoporosis in a postmenopausal woman
1.2 Documented T-score below -2.5 OR documentation that the patient is at high risk for bone fracture
1.3 Documented failure to respond, intolerance, or contraindication to any of the following: OR
Two oral bisphosphonates (alendronate, ibandronate)

One oral bisphosphonate and IV zoledronic acid (Reclast)

One oral bisphosphonate and denosumab (Prolia)

1.4 Documented severe osteoporosis with continued fracture after one year of continuous
bisphosphonate use
1.5 Patients with severe osteoporosis (T-score ≤ -3 or several vertebral fractures) can bypass
trial with bisphosphonates/Prolia based on evidence supporting maximized bone density
when receiving Evenity prior to bisphosphonates/Prolia
2. Exclusion Criteria
2.1 Combination therapy involving the use of romosozumab concurrently with another bone mineral density
modifying drug
2.2 Treatment of osteopenia
2.3 Evenity will not be covered if the member has previously been treated with Forteo or Tymlos
3. Approval Period
3.1 12 months (lifetime)
HCPCS Codes
J3111 Injection, romosozumab-aqqg, 1 mg
References
1. Evenity (romosozumab-aqqg) [prescribing information]. Thousand Oaks, CA: Amgen Inc; April 2020.
2. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American
College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal
osteoporosis-2020 update. Endocr Pract. 2020;26(suppl 1):1-46.
3. Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal
Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa048.
4. North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021
position statement of the North American Menopause Society. Menopause. 2021;28(9):973-997.
5. Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients with Osteoporosis at High
Risk for Fracture. Endocr Pract 2020; 26:777.

Created Date: 06/03/20
Effective Date: 06/03/20
Posted to Website: 01/01/22
Revision Date: 06/05/24
DISCLAIMER
This Medical Policy has been developed as a guide for determining medical necessity. The process of medical
necessity review also entails review of the most recent literature and physician review. Medical Policy is not
intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical
judgment in providing the most appropriate care. Health Alliance encourages input from providers when
developing and implementing medical policies. Benefit determinations are based on applicable contract language
in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not
guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please
contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.